Jessner’s lymphocytic infiltrate (syn. Jessner-Kanof syndrome)

LAST UPDATED: Aug 08, 2021

Introduction

Jessner’s lymphocytic infiltrate is a chronic benign T-cell lymphoproliferative condition of the skin. The characteristic lesions are non-scaly red papules, nodules and plaques, usually affecting the face, neck, and upper back.

This chapter is set out as follows:


Aetiology

  •  The cause is unknown

History

  • The conditions mainly affects adults younger than 50 years
  • Lesions are usually asymptomatic
  • Lesions may go through periods of remission and exacerbation over months or years, and seasonal activity is variable with most patients experiencing more active symptoms over the winter. Total spontaneous resolution may occur

Clinical findings

Distribution

  • Lesions can be solitary or numerous
  • The face, neck and upper back are the most commonly affected site

Morphology

  • Red tumid papules, nodules or plaques. Lesions occasionally have an arciform (arc-like) shape
  • The skin surface is normal with no scale, plugging or atrophy
  • Lesions enlarge gradually up to a size of 2 cm
  • The differential diagnosis includes sarcoid, lupus erythematosus tumidus, granuloma faciale, deep gyrate erythema (a variant of erythema annulare centrifugum) and cutaneous lymphoma

Clinical Images

Please refer to notes on image rights at bottom of the page with regards to individual image ownership.


Investigations

  • An incisional biopsy is required to confirm the diagnosis and exclude other conditions such as lymphoma
  • Histology - the epidermis is usually normal with no atrophy, follicular plugging or basement membrane thickening. There is a moderately dense superficial and deep perivascular dermal lymphocytic infiltrate. The infiltrate contains small mature lymphocytes, with occasional large lymphoid cells, plasmacytoid and plasma cells. Immunohistochemistry confirms a mixed lymphocytic infiltrate with a dominant population of CD8+ cells. Molecular analysis of both T‐cell and B‐cell populations are polyclonal on molecular analysis (reference: Rook's Textbook of Dermatology)
  • If the nature of the rash changes further biopsies may be needed

Management

  • Photoprotection may be of benefit as lesions often arise on UV-exposed sites  
  • Treatment is often unsatisfactory. Treatments sometimes tried include:
    • Potent topical or intralesional steroids
    • Oral hydroxychloroquine, which has an anti-inflammatory effect in the skin
  • The condition may resolve spontaneously

Disclaimer - the author PCDS cannot accept responsibility for any misleading or incorrect statements, and the management of individual patients remains the direct responsibility of the individual doctor. We do however hope that visitors to this site can contact us regarding comments that are considered misleading or incorrect so that we can continue to improve the site.

Image Rights - The PCDS would like to thank Dermatoweb, DermQuest (Galderma), and others who have contributed images. All named individuals and organisations maintain copyright for the relevant images.

Quick Links

The following pharmaceutical companies have had no involvement in the content of this website or in our conference programmes

Almirall
Galderma
Glenmark
Johnson & Johnson
La Roche-Posay
LEO Pharma
Pierre Fabre
Schuco